Atopic dermatitis and skin diseaseMeta-analysis of filaggrin polymorphisms in eczema and asthma: Robust risk factors in atopic disease
Section snippets
Data extraction and abstraction
The extant nosology of atopic disease is confusing, and terms such as eczema, atopic eczema, and atopic dermatitis are frequently used interchangeably in the literature. Recently, a World Allergy Organization report suggested the use of eczema as preferable to atopic dermatitis.8 Following this definition, the term eczema includes the disease formerly called atopic eczema or atopic dermatitis, as well as nonatopic eczema, whereas the term atopic eczema is reserved for those patients with eczema
Results
A total of 89 publications, including published abstracts (35 from PubMed and 54 from the ISI Web of Knowledge) were identified, of which 24 met the inclusion criteria for the current meta-analyses on eczema, asthma, or both. Tables I∗ and II† list all case-control and family-based studies included and show the estimated ORs and
Discussion
This meta-analysis of genetic association studies on the most common FLG variants in European populations involved 5,791 eczema cases and 26,454 control subjects, as well as 1,951 families. In addition, 3,138 asthma cases, 17,164 control subjects, and 4 family studies with 1,511 asthma-affected offspring were analyzed. This analysis provides the most comprehensive assessment thus far of the relevance of common FLG polymorphisms to eczema and represents the first meta-analysis on their effect on
References (57)
- et al.
Filaggrin in atopic dermatitis
J Allergy Clin Immunol
(2008) - et al.
Filaggrin mutations confer susceptibility to atopic dermatitis but not to asthma
J Allergy Clin Immunol
(2007) - et al.
Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data
J Allergy Clin Immunol
(2007) - et al.
Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003
J Allergy Clin Immunol
(2004) - et al.
Prevalent and rare mutations in the gene encoding filaggrin cause ichthyosis vulgaris and predispose individuals to atopic dermatitis
J Invest Dermatol
(2006) - et al.
Prevalent and low-frequency null mutations in the filaggrin gene are associated with early-onset and persistent atopic eczema
J Invest Dermatol
(2008) - et al.
Genetic association studies
Lancet
(2005) - et al.
Meta-analysis in clinical trials
Control Clin Trials
(1986) - et al.
Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations
J Allergy Clin Immunol
(2006) - et al.
Filaggrin mutations in children with severe atopic dermatitis
J Invest Dermatol
(2007)
Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis
J Invest Dermatol
Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood
J Invest Dermatol
Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march
J Allergy Clin Immunol
Loss-of-function mutations in the filaggrin gene and alopecia areata: strong risk factor for a severe course of disease in patients comorbid for atopic disease
J Invest Dermatol
Loss-of-function mutations in the filaggrin gene and allergic contact sensitization to nickel
J Invest Dermatol
Two common loss-of-function mutations within the filaggrin gene predispose for early onset of atopic dermatitis
J Invest Dermatol
Filaggrin gene mutations are associated with asthma and eczema in later life
J Allergy Clin Immunol
Fleshing out filaggrin phenotypes
J Invest Dermatol
Advances in asthma and allergy genetics in 2007
J Allergy Clin Immunol
Lack of filaggrin expression in the human bronchial mucosa
J Allergy Clin Immunol
Atopic dermatitis
N Engl J Med
The genetics of atopic dermatitis
J Allergy Clin Immunol
Filaggrin loss-of-function mutations and association with allergic diseases
Pharmacogenomics
Filaggrin variants confer susceptibility to asthma
J Allergy Clin Immunol
Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis
Nat Genet
Gene-environment interaction in the onset of eczema in infancy: filaggrin loss-of-function mutations enhanced by neonatal cat exposure
PLoS Med
Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema
Nat Genet
Filaggrin mutations, atopic eczema, hay fever, and asthma in children
J Allergy Clin Immunol
Cited by (354)
Diagnosing Atopic Dermatitis in Skin of Color
2023, Dermatologic ClinicsExtracellular Matrix Remodeling in Atopic Dermatitis Harnesses the Onset of an Asthmatic Phenotype and Is a Potential Contributor to the Atopic March
2023, Journal of Investigative DermatologyEpigenetics of allergic diseases: Allergies, eczema, asthma, and allergic rhinitis
2023, Epigenetics in Human Disease, Third EditionEczema among adolescents in Kuwait: Prevalence, severity, sleep disturbance, antihistamine use, and risk factors
2023, World Allergy Organization JournalAtopic Dermatitis and Allergic Contact Dermatitis
2022, Allergy Essentials
Supported by grant 01GS0818 of the German Ministry of Education and Research (BMBF) as part of the National Genome Research Network (NGFN). S. Weidinger is supported by a Heisenberg fellowship (WE 2678/4-1) of the DFG, grant C49-08 of the University Hospital Rechts der Isar, Technische Universität München, and a grant from the Wilhelm-Vaillant-Stiftung. S. Weidinger and S. Wagenpfeil are supported by research grants KKF-07/04 and KKF-27/05 of the University Hospital Rechts der Isar, Technische Universität München.
Disclosure of potential conflict of interest: S. Wagenpfeil has received research support from Bundesministerium für Bildung und Forschung. S. J. Brown has received research support from the British Skin Foundation, the British Society of Paediatric Dermatology, and Action Medical Research. H. J. Cordell has received research support from the Wellcome Trust, the Medical Research Council (UK), and Action Medical Research. A. D. Irvine served as a consultant for Novartis, has received research support from the Children's Medical and Research Foundation and the Health Research Board Ireland, and has provided medicolegal consultations. The rest of the authors have declared that they have no conflict of interest.
- ∗
These authors contributed equally to this work.